Rhumbline Advisers Athira Pharma, Inc. Transaction History
Rhumbline Advisers
- $103 Billion
- Q1 2024
A detailed history of Rhumbline Advisers transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 1,532 shares of ATHA stock, worth $3,937. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,532
Previous 1,532
-0.0%
Holding current value
$3,937
Previous $3,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding ATHA
# of Institutions
83Shares Held
22.3MCall Options Held
77.1KPut Options Held
42.4K-
Perceptive Advisors LLC New York, NY5.4MShares$13.9 Million0.31% of portfolio
-
Baker Bros. Advisors LP New York, NY3.15MShares$8.11 Million0.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.63MShares$4.2 Million0.0% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA1.49MShares$3.84 Million2.38% of portfolio
-
Simplify Asset Management Inc. New York, NY1.49MShares$3.84 Million0.26% of portfolio
About Athira Pharma, Inc.
- Ticker ATHA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 37,817,700
- Market Cap $97.2M
- Description
- Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...